The GLP-1 Regulatory Picture and Compounding, in 2026

What this article is and is not

This is a regulation-and-market orientation, written as a careful third party. It does not describe what GLP-1 medicines do in patients, does not say whether any preparation is available, and does not name or compare products. ³ Those are matters for prescribers, for the manufacturers, and for the FDA. The aim here is to explain the moving parts so a reader understands why the topic keeps appearing in the news.

The shortage-list mechanism

FDA drug shortage list

A public list the FDA maintains of drugs determined to be in shortage. Whether a drug appears on, or is removed from, this list can affect the regulatory considerations around compounding versions of that drug. ¹

In general terms, federal law limits compounding that is essentially a copy of a commercially available, approved drug. ² Shortage status interacts with that principle, which is why the shortage list is central to the GLP-1 discussion. When a drug moves on or off the list, the surrounding compounding considerations can move with it. ¹² Because that status is dynamic, any statement tied to it can be accurate one month and outdated the next.

How the 503A and 503B lanes fit

The two-lane structure still applies. A 503A pharmacy compounds for an identified patient under a prescription, overseen mainly by its state board, while a 503B outsourcing facility registers with the FDA and follows Current Good Manufacturing Practice. ² The conditions each lane operates under shape what is permissible, and they should be read alongside shortage considerations rather than in isolation. ²

• Shortage status is dynamic. A drug can be added to or removed from the FDA shortage list, and that change carries regulatory weight. ¹
• Copying approved drugs is limited. Federal law restricts compounding that is essentially a copy of a commercially available approved product. ²
• Lane rules still apply. 503A and 503B conditions sit on top of any shortage considerations. ²
• FDA guidance evolves. The agency issues and revises guidance and enforcement positions over time, so the picture is not fixed. ²³

Why this matters for pharmacy marketing

For marketing, the volatility is the whole story. Copy that leans on a specific shortage status, a specific product, or an implied availability can become inaccurate quickly and can also run into advertising-policy problems on the platforms. ³ The durable approach is education that explains the framework, points to primary sources, and avoids product and availability claims entirely. That posture protects both compliance and credibility while the underlying rules keep moving.

Nothing here is legal or clinical advice. A pharmacy should work from current FDA materials and its own counsel and state board guidance when making decisions. ¹²